Abstract
It has become clear that almost any drug or chemical substance administered to the mother is able to cross the placenta to some extent, unless it is metabolized or altered during passage, or else its molecular size and low lipid solubility do not allow transplacental transfer. A number of transport systems have been identified in the placenta, which recognizes a wide variety of pharmacological active drugs as substrates. In recent years, research on human placental transporters has been developing due to the increase of knowledge technology in pharmacology. In this review we will focus on the main placental transporters which are known today. The P-glycoprotein (P-gp), Breast cancer resistance protein (BCRP/ABCG2) and Multidrug resistance associated protein 2 (MDR2) transporters are expressed at the apical surface of the syncytiotrophoblast, and have a protective effect. Transporters for 5-HT (SERT) and NE (NET) are also expressed at the apical surface and regulate extracellular concentrations of monoamines. The physiologic function of Multidrug resistance associated protein (MRP) transporters (which is expressed at the basal surface of the syncytiotrophoblast) may be the removal of metabolic end products from the fetus. Some of the members of the organic anion transporters are also expressed at the basolateral surface of the syncytiotrophoblast.
Keywords: Breast cancer resistance protein / mitoxantrone resistance protein, monoamine transporters, multidrug resistance associated protein, organic anion transporters, P-glycoprotein, transplacental transfer, placenta, fetus, syncytiotrophoblast, xenobiotics, pregnancy, teratogenic effects, Transplacental pharmacotherapy
Current Pharmaceutical Biotechnology
Title: Drug Transport Across the Placenta
Volume: 12 Issue: 5
Author(s): Tamar Eshkoli, Eyal Sheiner, Zvi Ben-Zvi, Valeria Feinstein and Gershon Holcberg
Affiliation:
Keywords: Breast cancer resistance protein / mitoxantrone resistance protein, monoamine transporters, multidrug resistance associated protein, organic anion transporters, P-glycoprotein, transplacental transfer, placenta, fetus, syncytiotrophoblast, xenobiotics, pregnancy, teratogenic effects, Transplacental pharmacotherapy
Abstract: It has become clear that almost any drug or chemical substance administered to the mother is able to cross the placenta to some extent, unless it is metabolized or altered during passage, or else its molecular size and low lipid solubility do not allow transplacental transfer. A number of transport systems have been identified in the placenta, which recognizes a wide variety of pharmacological active drugs as substrates. In recent years, research on human placental transporters has been developing due to the increase of knowledge technology in pharmacology. In this review we will focus on the main placental transporters which are known today. The P-glycoprotein (P-gp), Breast cancer resistance protein (BCRP/ABCG2) and Multidrug resistance associated protein 2 (MDR2) transporters are expressed at the apical surface of the syncytiotrophoblast, and have a protective effect. Transporters for 5-HT (SERT) and NE (NET) are also expressed at the apical surface and regulate extracellular concentrations of monoamines. The physiologic function of Multidrug resistance associated protein (MRP) transporters (which is expressed at the basal surface of the syncytiotrophoblast) may be the removal of metabolic end products from the fetus. Some of the members of the organic anion transporters are also expressed at the basolateral surface of the syncytiotrophoblast.
Export Options
About this article
Cite this article as:
Eshkoli Tamar, Sheiner Eyal, Ben-Zvi Zvi, Feinstein Valeria and Holcberg Gershon, Drug Transport Across the Placenta, Current Pharmaceutical Biotechnology 2011; 12 (5) . https://dx.doi.org/10.2174/138920111795470877
DOI https://dx.doi.org/10.2174/138920111795470877 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epilogue
Current Pharmaceutical Design HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Molecular Treatment of Different Breast Cancers
Anti-Cancer Agents in Medicinal Chemistry Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design Drug Targeting of Estrogen Receptor Signaling in the Cardiovascular System: Preclinical and Clinical Studies
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Recent Advancemnts in Biodegradable Ocular Implants
Current Drug Delivery Preface - Special Issue “Mini-Reviews in Medicinal Chemistry” Proceedings of the Twentieth Anniversary of the Faculty of Pharmacy of the University of Calabria
Mini-Reviews in Medicinal Chemistry Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer
Reviews on Recent Clinical Trials Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Immunological Properties of Donkeys Milk: Its Potential Use in the Prevention of Atherosclerosis
Current Pharmaceutical Design Editorial (Thematic Issue: Targeting Epithelial-to-Mesenchymal Transition for Cancer Therapy)
Current Pharmaceutical Design Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Editorial (Thematic Issue: Combined Cancer Therapy)
Current Pharmaceutical Design